



Tuberculosis Country Profile 2021 Philippines

Source: Global tuberculosis report 2021. Geneva: World Health Organization

Disclaimer: Tuberculosis country profiles are generated automatically based on data reported by countries and which are held in WHO's global TB database.

Tuberculosis profile: Philippines

Population 2020: 110 million

Estimates of TB burden*, 2020

	Number	(Rate per 100 000 population)
Total TB incidence	591 000 (335 000-918 000)	539 (306-838)
HIV-positive TB incidence	12 000 (5 300-23 000)	11 (4.8-21)
HIV-negative TB mortality	31 000 (27 000-35 000)	28 (25-32)
HIV-positive TB mortality	490 (280-760)	0.45 (0.26-0.69)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2020	43% (28-77)
TB patients facing catastrophic total costs, 2017	42% (39-46)
TB case fatality ratio (estimated mortality/estimated incidence), 2020	6% (3-9)

TB case notifications, 2020

Total new and relapse	256 541
- % tested with rapid diagnostics at time of diagnosis	60%
- % with known HIV status	33%
- % pulmonary	98%
- % bacteriologically confirmed [^]	43%
- % children aged 0-14 years	7%
- % women (aged ≥15 years)	30%
- % men (aged ≥15 years)	63%
Total cases notified	263 300

TB/HIV care in new and relapse TB patients, 2020

	Number	(%)
Patients with known HIV status who are HIV-positive	898	1%
- on antiretroviral therapy	898	100%

Drug-resistant TB care**, 2020

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases [^]	85%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases [^]	95%
Laboratory-confirmed cases - MDR/RR-TB ^{^^}	6 279
Patients started on treatment - MDR/RR-TB ^{^^^}	4 944
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^{^^}	23
Patients started on treatment - pre-XDR-TB or XDR-TB ^{^^^}	23
MDR/RR-TB cases tested for resistance to any fluoroquinolone	878

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2019	86%	342 777
Previously treated cases, excluding relapse, registered in 2019	79%	7 994
HIV-positive TB cases registered in 2019	78%	1 590
MDR/RR-TB cases started on second-line treatment in 2018	67%	5 902
XDR-TB cases started on second-line treatment in 2018	66%	50

TB preventive treatment, 2020


% of HIV-positive people (newly enrolled in care) on preventive treatment	49%
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	5.6% (5.1-6.2)

TB financing

National TB budget, 2021 (US\$ millions)	314
- Funding source, domestic	26%
- Funding source, international	22%
- unfunded	52%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)




HIV-negative TB mortality

(Rate per 100 000 population per year)




Incidence, Notified cases by age group and sex, 2020

(Number)




Cases attributable to five risk factors, 2020

(Number)



Total budget

(US\$ millions)



* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.
 ** RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone
 ^ Calculated for pulmonary cases only
 ^^ Includes cases with unknown previous TB treatment history
 ^^ Includes patients diagnosed before 2020 and patients who were not laboratory-confirmed